Trump urged to keep Biden’s Medicare drug price cuts
A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end negotiations."
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Trump pulls back Biden drug pricing action
The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.
Trump Revokes Biden's Order to Lower Drug Prices for Medicare
President Trump rescinded a Biden-era Executive Order that would have lowered the copays for some drugs to $2 for Medicare enrollees.
Fact Check: Did Trump Raise Prescription Drug Prices?
Trump reversed former President Joe Biden's order on "Lowering Prescription Drug Costs for Americans" on Monday.
Trump Order Walks Back Biden-Era Effort To Lower Prescription Drug Prices. Here's Context
On Day 1 of his second term of office, Trump rescinded Biden's Executive Order 14087, "Lowering Prescription Drug Costs for Americans." Trump's action ha
Trump executive order on prescription drug costs
President Trump has rolled back a Biden-era executive order aimed at lowering prescription drug costs for Americans, raising concerns among Medicare and Medicaid recipients. FOX 5’s Linda Schmidt looks at what this means for patients and what impact it could have on existing policies,
No, Trump did not get rid of Medicare’s $35 insulin cap
Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly out-of-pocket price cap, which is set by law.
Money Morning8d
Eli Lilly Faces ‘Death Cross’ Selloff: This is the Stock's Next Target Price...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
STAT10d
Eli Lilly CEO says the company sees ‘significant common cause’ with Trump administration
Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
FiercePharma11d
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
STAT10d
Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...